Tags

Type your tag names separated by a space and hit enter

Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group.

Abstract

OBJECTIVE

To compare the effects of placebo and GLA on the course of mild diabetic neuropathy over 1 yr.

RESEARCH DESIGN AND METHODS

We entered 111 patients with mild diabetic neuropathy from seven centers into a randomized, double-blind, placebo-controlled parallel study of GLA at a dose of 480 mg/day. MNCV, SNAP, CMAP, hot and cold thresholds, sensation, tendon reflexes, and muscle strength were assessed by standard tests in upper and lower limbs.

RESULTS

For all 16 parameters, the change over 1 yr in response to GLA was more favorable than the change with placebo, and for 13 parameters, the difference was statistically significant. Sex, age, and type of diabetes did not influence the result, but treatment was more effective in relatively well-controlled than in poorly-controlled diabetic patients.

CONCLUSIONS

GLA had a beneficial effect on the course of diabetic neuropathy.

Authors+Show Affiliations

,

UMDS, London, UK.

, , , , , , , ,

Source

Diabetes care 16:1 1993 Jan pg 8-15

MeSH

Analysis of Variance
Anti-Inflammatory Agents, Non-Steroidal
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetic Neuropathies
Double-Blind Method
Female
Humans
Linolenic Acids
Male
Middle Aged
Motor Neurons
Neural Conduction
Neurologic Examination
Neurons, Afferent
Reflex
gamma-Linolenic Acid

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8380765

Citation

Keen, H, et al. "Treatment of Diabetic Neuropathy With Gamma-linolenic Acid. the gamma-Linolenic Acid Multicenter Trial Group." Diabetes Care, vol. 16, no. 1, 1993, pp. 8-15.
Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care. 1993;16(1):8-15.
Keen, H., Payan, J., Allawi, J., Walker, J., Jamal, G. A., Weir, A. I., ... Sampson, M. (1993). Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care, 16(1), pp. 8-15.
Keen H, et al. Treatment of Diabetic Neuropathy With Gamma-linolenic Acid. the gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care. 1993;16(1):8-15. PubMed PMID: 8380765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. A1 - Keen,H, AU - Payan,J, AU - Allawi,J, AU - Walker,J, AU - Jamal,G A, AU - Weir,A I, AU - Henderson,L M, AU - Bissessar,E A, AU - Watkins,P J, AU - Sampson,M, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez SP - 8 EP - 15 JF - Diabetes care JO - Diabetes Care VL - 16 IS - 1 N2 - OBJECTIVE: To compare the effects of placebo and GLA on the course of mild diabetic neuropathy over 1 yr. RESEARCH DESIGN AND METHODS: We entered 111 patients with mild diabetic neuropathy from seven centers into a randomized, double-blind, placebo-controlled parallel study of GLA at a dose of 480 mg/day. MNCV, SNAP, CMAP, hot and cold thresholds, sensation, tendon reflexes, and muscle strength were assessed by standard tests in upper and lower limbs. RESULTS: For all 16 parameters, the change over 1 yr in response to GLA was more favorable than the change with placebo, and for 13 parameters, the difference was statistically significant. Sex, age, and type of diabetes did not influence the result, but treatment was more effective in relatively well-controlled than in poorly-controlled diabetic patients. CONCLUSIONS: GLA had a beneficial effect on the course of diabetic neuropathy. SN - 0149-5992 UR - https://www.unboundmedicine.com/medline/citation/8380765/full_citation L2 - https://medlineplus.gov/diabeticnerveproblems.html DB - PRIME DP - Unbound Medicine ER -